Health Care

GlaxoSmithKline and Alnylam Pharmaceuticals recently announced that BIO Ventures for Global Health will administer the Intellectual Property (IP) Pool to aid in the discovery and development of new treatments for neglected tropical diseases.

Disease resistant animals, environmentally friendly livestock, pharmaceuticals produced by goats - are these really possible?

Sustainable development is no small undertaking for international companies looking to meet today’s energy, food and environmental needs without compromising the Earth’s resources or its future. The innovative solution these corporate leaders are turning to is biotechnology, whether it’s to augment agricultural productivity, reduce greenhouse gas emissions, create an innovative disease therapy or diminish the use of pesticides.

With the Senate no longer filibuster-proof, the future of the health care bill is fairly murky. In early January, Congress was deep into negotiations on a final version, which includes language that would be a major shot in the arm for the biotechnology industry and provide great benefits to patients.

Personalized medicine involves using the advanced tools of molecular genetics and diagnostics to predict how patients will respond to drugs, reducing harmful side effects and increasing benefit. In addition, the panoply of technologies enabling this revolution in medicine can produce a personal medical profile that can guide the physician toward selecting the most appropriate drug or treatment regimen and help individuals stave off diseases before they manifest themselves. This dual combination of diagnostic and treatment technologies is at the heart of personalized medicine and is poised to transform healthcare dramatically.

Technological innovation promises to redefine health care as we know it.

New vaccines employing biotech innovations are changing the way we prevent illness.

We all know that California has been hit hard by the current recession. Sadly most of the state is facing dire economic realities that go much deeper than that.  However, its status as the world’s undisputed epicenter of biotechnology has not been tarnished one bit, according to a new survey released by the California Healthcare Institute.

Ttoday, modern biotechnology offers the opportunity to go well beyond blocking the production of proteins to actually silencing them.

Danny Levine of the Burrill Report conducted a podcast with BIO President & CEO Jim Greenwood today on BIO's public priorities for 2010.

March 14 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the "Proposed Rule: Supplemental Applications Proposing Labelling Changes for Approved Drugs and Biological Products."
March 10 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments to the docket regarding “Complex Issues in Developing Drug and Biologics Products for Rare Diseases.” Comments are being provided in two areas; general comments on the challenges of rare disease drug development, and specific comments in response to the public workshop.
March 4 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Request for Nominations: Drug Products that Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.”
February 3 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act.”
January 31 2014
The Biotechnology Industry Organization (BIO) respectfully submits these comments in response to the Generic Pharmaceutical Association (GPhA) Citizen Petition requesting the Food and Drug Administration (FDA) to “implement its INN naming policy equally to all biologics” and to require “all biologics approved under the Section 351(k) pathway…share the same INN [International Nonproprietary Name] as the RPP [reference protein product]” (the GPhA Petition).
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
March 25 2014
The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF) commend Indiana Governor Mike Pence for signing legislation today designed to create a pathway for the substitution of interchangeable biologic medicines.
March 5 2014
Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed